Litigation Details for Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)

Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)

Docket		Date Filed	2018-12-19
Court	District Court, D. Delaware	Date Terminated	2020-02-11
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,758,891; 7,820,788; 7,923,536; 8,034,375; 8,138,229; 8,268,348; 8,314,156; 8,853,260; 9,101,543; 9,101,545; 9,393,318; 9,511,046; 9,597,409
Link to Docket	External link to docket

Details for Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-19				External link to document
2018-12-19	17		1402 Patents-in-Suit in twelve separate counts, as follows: United States Patent Nos. 7,758,891 (891 …Tithe of Patent : _?) “Glanmed Use 0°: I fF 28-36: Ex A 7,758,891 | “Combinations and modes of | “A method…891 patent,” Count I; 7,820,788 (788 patent,” Count ID), 7,923,536 ¢°536 patent,” Count UD), 8,034,375 (… (°375 patent,” Count IV), 8,138,229 (229 patent,” Count V), 8,268,348 (348 patent,” Count V1), 8,314,…8,314,156 (° 156 patent,” Count VII), 8,853,260 (°°260 patent,” Count VII), 9,101,543 (543 patent,” Count IX	External link to document
2018-12-19	36	Order - -Memorandum and Order	The patents-in-suit include United States Patent Nos. 7,758,891 ("the '891 patent"),…in a patent or the use of which is claimed in a patent before the expiration of such patent. …infringement of twelve patents under 35 U.S.C. § 271(e). (D.I. 1). The patents-in-suit 1 relate to various… ("the '788 patent"), 7,923,536 (''the '536 patent"), 8,034,375 ("…"the '375 patent"), 8,138,229 ("the '229 patent"), 8,268,348 (''	External link to document
2018-12-19	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,758,891 B2 ;7,820,788 B2 ;7,923,536… 11 February 2020 1:18-cv-02019 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Abraxis BioScience v. HBT Labs, Inc. (1:18-cv-02019): Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Abraxis BioScience, LLC sued HBT Labs, Inc. in the U.S. District Court for the District of Delaware after HBT submitted an Abbreviated New Drug Application seeking approval for a generic version of Abraxane, an albumin-bound paclitaxel product. The case was an ANDA patent action under the Hatch-Waxman Act. The dispute centered on method-of-use protection for nanoparticle albumin-bound paclitaxel, rather than on a conventional small-molecule composition patent challenge.

The docket identifies the action as Abraxis BioScience, LLC v. HBT Labs, Inc., No. 1:18-cv-02019-RGA, filed in the District of Delaware. The case was later terminated following resolution between the parties. The public record does not establish a judicial finding that HBT’s proposed product was invalid or noninfringing.

What drug and patent were at issue in Abraxis v. HBT Labs?

The product was Abraxane, the brand name for paclitaxel protein-bound particles for injectable suspension, marketed by Abraxis and later associated with Celgene and Bristol Myers Squibb.

Abraxane is an intravenous formulation in which paclitaxel is associated with albumin nanoparticles. The formulation was approved for several indications, including:

• Metastatic breast cancer after failure of combination chemotherapy;
• Locally advanced or metastatic non-small-cell lung cancer in combination with carboplatin;
• Metastatic adenocarcinoma of the pancreas in combination with gemcitabine.

HBT’s ANDA product was intended to be a generic paclitaxel protein-bound particle product. The litigation was therefore commercially significant because approval of a competing product could affect Abraxane sales across multiple indications.

Product and case overview

Item	Information
Brand drug	Abraxane
Active ingredient	Paclitaxel
Delivery system	Albumin-bound nanoparticle formulation
Dosage form	Intravenous injectable suspension
NDA holder at original approval	Abraxis BioScience, LLC
Defendant	HBT Labs, Inc.
Case number	1:18-cv-02019-RGA
Court	U.S. District Court for the District of Delaware
Action type	Hatch-Waxman ANDA litigation
Filing year	2018
Primary commercial issue	Generic entry for albumin-bound paclitaxel
Disposition	Terminated after party resolution

What patent did Abraxis assert against HBT Labs?

The case is associated with U.S. Patent No. 8,980,349, which covers methods involving nanoparticle paclitaxel formulations, including treatment methods using albumin-bound paclitaxel.

The asserted patent was a method-of-use patent. That distinction matters because a method patent typically does not prevent all manufacture or sale of the active ingredient. Its value depends on the scope of the claimed treatment method, the indications covered, the proposed generic labeling, and whether the defendant’s ANDA product would induce infringement.

Method-of-use patent issues

The principal questions in an ANDA case involving a method patent are generally:

1. Whether the proposed generic label instructs physicians to use the product in a patented manner;
2. Whether the ANDA filing constitutes an artificial act of infringement under 35 U.S.C. § 271(e)(2);
3. Whether the patent claims are valid and enforceable;
4. Whether a section viii statement or other labeling restriction can avoid infringement;
5. Whether the proposed product’s formulation and administration instructions fall within the claims.

The Abraxane litigation involved the relationship between the generic product’s proposed labeling and the patented use of albumin-bound paclitaxel. That structure differs from litigation focused solely on particle size, excipient composition, manufacturing process, or pharmaceutical composition claims.

When was Abraxis v. HBT Labs filed?

Abraxis filed the action in December 2018 after receiving notice of HBT’s ANDA certification concerning the Abraxane patent listing. The case was assigned to Judge Richard G. Andrews in the District of Delaware.

The filing triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions and any later court order. The stay generally prevents FDA approval of the ANDA during the statutory period unless the litigation is resolved earlier or the court issues an applicable judgment.

Hatch-Waxman procedural timeline

Event	Timing
HBT ANDA filing	Before the 2018 complaint
Patent notice and certification	Before or in connection with the complaint
Abraxis complaint	December 2018
Federal case	1:18-cv-02019-RGA
Patent dispute	Abraxane method-of-use protection
Case resolution	After filing and before a publicly reported merits judgment
Public merits determination	No reported final trial judgment establishing invalidity or noninfringement

The case was not resolved through a published district-court opinion adjudicating the full validity and infringement merits of the patent.

Did HBT Labs file a Paragraph IV challenge?

The litigation arose from HBT’s ANDA filing and patent certification process. The case should be treated as a Hatch-Waxman challenge involving an asserted Abraxane patent. The publicly available case materials do not provide a reported final judgment that conclusively describes each certification and every claim ultimately at issue.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a Paragraph IV notice can create a private right of action for the patent owner under section 271(e)(2). A lawsuit filed within 45 days can trigger the statutory stay of FDA approval.

For commercial analysis, the critical point is that HBT’s regulatory filing created a pathway to challenge Abraxis’s patent position before generic launch. The litigation did not produce a published invalidity decision that would have broadly removed the patent from the Abraxane estate.

What was the litigation status and final outcome?

The case was terminated after the parties reached a resolution. The public docket does not provide a reported trial verdict or a detailed opinion setting out the economic terms of the settlement.

The available record therefore supports the following conclusions:

• The litigation ended without a public merits judgment deciding the patent’s validity;
• The docket does not establish that HBT obtained an immediate right to launch;
• The record does not establish that HBT’s ANDA was finally blocked through a permanent injunction;
• The settlement terms, including any authorized launch date, royalty, license, or supply arrangement, were not publicly disclosed in the reported court record.

Settlement analysis

Hatch-Waxman settlements commonly contain some combination of:

• A negotiated generic entry date;
• A license to the asserted patent;
• A manufacturing or supply arrangement;
• A no-challenge provision;
• Royalty payments;
• Patent expiration or regulatory-contingency provisions;
• Terms addressing other Abraxane patents or future litigation.

The publicly available docket for this case does not provide enough detail to attribute any particular launch date or payment term to the Abraxis-HBT agreement. Analysts should not treat the case termination as proof that the generic was cleared for immediate commercial launch.

What was the FDA and Orange Book status of Abraxane?

Abraxane was approved by the FDA under NDA 021660. The FDA Orange Book listed patents associated with the product, including patents covering the formulation and therapeutic uses of paclitaxel protein-bound particles.

Orange Book listings can affect ANDA timing even when the listed patents do not cover every aspect of the generic product. A listed method-of-use patent can be relevant to the ANDA applicant’s certification and labeling strategy. A generic applicant may seek to omit a patented indication through a section viii statement, but the feasibility of that approach depends on the patent claims and the FDA-approved labeling.

Regulatory implications

The HBT case illustrates four separate regulatory questions:

1. Approval status: Whether FDA completed review of HBT’s ANDA;
2. Patent certification: Whether HBT certified against the relevant Orange Book listings;
3. Approval timing: Whether the 30-month stay delayed approval;
4. Commercial launch: Whether any settlement authorized entry before patent expiration.

FDA approval and commercial launch are separate events. Even if an ANDA receives approval, a generic may remain off the market because of a settlement, a later patent dispute, manufacturing constraints, or a business decision.

How strong was the Abraxis patent estate?

The Abraxis estate had meaningful value because Abraxane was a complex injectable product with formulation, manufacturing, and method-of-use features that are more difficult to design around than a conventional tablet.

Its strength was mixed by patent category.

Composition and formulation protection

Albumin-bound paclitaxel products depend on a defined nanoparticle structure and injectable formulation. Relevant claim issues can include:

• Particle size;
• Paclitaxel-to-albumin relationships;
• Absence or presence of conventional solvents;
• Reconstitution characteristics;
• Stability;
• Administration parameters;
• Manufacturing controls.

These features can create technical barriers, but the commercial scope depends on the precise claim language and the generic’s formulation.

Method-of-use protection

Method claims may have substantial commercial value when:

• The patented indication is included in the generic label;
• Physicians are expected to use the product for that indication;
• The indication is commercially important;
• The generic cannot realistically omit the use without limiting market access.

Method patents are weaker where the generic can obtain approval with a clean label that omits the patented indication or where the accused conduct depends on discretionary physician use.

Manufacturing and process barriers

Albumin-bound paclitaxel is an injectable nanoparticle product. Generic development requires control over particle formation, sterile processing, reconstitution, dose uniformity, and product performance. These issues can create regulatory and manufacturing barriers independent of patent validity.

The manufacturing burden does not itself establish patent infringement. It can, however, reduce the number of viable generic competitors and increase the cost of an early launch.

What generic entry risks existed for Abraxane?

The principal risk was a successful ANDA launch by HBT or another applicant. Generic entry could have affected Abraxane through:

• Price erosion;
• Hospital and oncology-practice substitution;
• Loss of formulary preference;
• Reduced market share across several indications;
• Pressure on contracting and rebates;
• Lower revenue from high-volume pancreatic and breast cancer use.

The risk was moderated by the complexity of the product and by the need to address both regulatory approval and patent exposure.

Generic launch scenarios

Scenario	Effect on Abraxis
No approval or litigation defeat	Continued branded exclusivity, subject to other competitors
Delayed approval after settlement	Preserved revenue until negotiated entry
Authorized launch before all patents expire	Gradual erosion, potentially limited by settlement terms
Multiple generic approvals	Faster price and share erosion
Single generic launch	Lower initial erosion but substantial contracting pressure
Product-specific manufacturing failure	Delayed competitive impact despite legal clearance

The case alone does not establish which scenario ultimately applied to HBT.

Which companies challenged Abraxane patents?

Abraxane faced broader generic competition and patent activity beyond the HBT case. Potential challengers in the Abraxane market included companies developing generic paclitaxel protein-bound particles, such as major injectable-drug manufacturers and specialty generic companies.

The competitive analysis must distinguish between:

• A company filing an ANDA;
• A company litigating a patent;
• A company receiving FDA approval;
• A company actually launching;
• An authorized generic or licensed entrant.

A patent case involving one ANDA applicant does not necessarily determine the timing of other applicants’ entry. Each applicant may have different certifications, formulations, settlements, and launch rights.

How does Abraxis v. HBT compare with ordinary generic drug litigation?

The case had a more complex technical profile than litigation involving a simple oral tablet.

Issue	Conventional generic tablet	Abraxane-type product
Main technical focus	Active ingredient and bioequivalence	Nanoparticle formulation and injectable performance
Manufacturing burden	Often moderate	High
Formulation design-around	Often available	More difficult if core particle characteristics are claimed
Regulatory review	Standard ANDA pathway	Complex injectable product review
Patent mix	Composition, formulation, use	Formulation, process, particle, and method claims
Substitution risk	Often rapid after launch	May depend on clinical practice and institutional purchasing

The HBT litigation therefore had both legal and technical barriers. A successful patent defense would not necessarily guarantee immediate market entry if HBT still faced FDA or manufacturing requirements.

What does the case mean for investors and licensing teams?

The case demonstrates that Abraxane’s commercial protection did not depend solely on a single patent expiration date. The relevant protection was a combination of:

• Orange Book-listed patents;
• Method-of-use claims;
• Product complexity;
• FDA review requirements;
• Manufacturing capability;
• Settlement restrictions;
• The number and timing of competing ANDAs.

For licensing analysis, a settlement without public terms creates a valuation constraint. It is possible to confirm that litigation ended, but not to assign a negotiated launch date or royalty stream without the agreement or a regulatory disclosure.

For revenue forecasting, the most important variables were the number of approved generic applicants, the earliest permitted launch date, the breadth of any label carve-outs, and whether the generic could reproduce the albumin-bound nanoparticle product at commercial scale.

Key Takeaways

• Abraxis BioScience sued HBT Labs in the District of Delaware in 1:18-cv-02019-RGA over an ANDA for generic Abraxane.
• The dispute involved paclitaxel protein-bound particles, an injectable nanoparticle product.
• The litigation centered on method-of-use patent protection, including U.S. Patent No. 8,980,349.
• The case ended after party resolution rather than a reported merits judgment.
• The public record does not establish HBT’s exact authorized launch date, settlement payment, royalty, or license scope.
• Abraxane’s competitive protection depended on patents, FDA approval, complex manufacturing, and the timing of other generic applicants.
• Case termination should not be interpreted as an adjudication that the patent was invalid or that HBT had immediate launch rights.

FAQs About Abraxis BioScience v. HBT Labs

Was Abraxis v. HBT Labs an ANDA patent lawsuit?

Yes. The case was a Hatch-Waxman action concerning HBT’s proposed generic version of Abraxane.

Did HBT Labs win the patent case?

The public record does not show a merits judgment awarding HBT a victory on invalidity or noninfringement. The action was terminated after resolution between the parties.

Did the case concern ordinary paclitaxel?

It concerned paclitaxel delivered as an albumin-bound nanoparticle formulation, the technology used in Abraxane.

Did the litigation determine when HBT could launch?

The reported court record does not disclose a definitive HBT launch date. Settlement terms may have addressed entry, but those terms are not established by the public docket alone.

Are Abraxane patents still relevant after this case ended?

Yes. The HBT case involved one applicant and particular patent issues. Other Abraxane patents, applicants, regulatory actions, and settlements could affect market exclusivity independently.

References

1. Abraxis BioScience, LLC v. HBT Labs, Inc., No. 1:18-cv-02019-RGA, U.S. District Court for the District of Delaware, docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Abraxane (paclitaxel protein-bound particles for injectable suspension) prescribing information. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,980,349. USPTO.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

6. Patent Act, 35 U.S.C. § 271(e)(2).